RPG Life Sciences Limited has informed the Exchange about Investor Presentation
RPGLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
RPG Life Sciences submitted its Q1 FY26 investor presentation to the exchanges, detailing the unaudited financial results for the quarter ended June 30, 2025. Revenue from operations grew 2.1% year-on-year to Rs. 168.9 crore, but profit after tax (PAT) declined 1.8% to Rs. 26.3 crore, and EBITDA margin contracted 100 basis points to 24.1%. Segment-wise, Domestic Formulations led with 9.5% growth to Rs. 115.5 crore, while International Formulations slipped 2.7% to Rs. 32.5 crore and the API segment fell sharply by 22.4% to Rs. 19.6 crore due to a fire incident in one of the manufacturing blocks. The company highlighted that it remains debt-free with ROCE of 32.9% in FY25, and ICRA has reaffirmed its long-term rating at A+ with a stable outlook. Management outlined a 7-pillar growth roadmap including an M&A framework with defined criteria, plans to scale the immunosuppressant portfolio to Rs. 200+ crore, and growing the Naprosyn brand to Rs. 100+ crore.
The mixed quarterly show—revenue growth offset by margin pressure and a sharp API decline from the fire incident—may keep near-term sentiment cautious, though the debt-free balance sheet, upgraded credit rating, and clearly articulated multi-year growth targets offer longer-term support for the stock.